MMTV‐EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone‐responsive tissues

Correlative analyses of tumors and patient‐derived cell lines of the human reproductive system suggest that overexpression of EGF contributes to the oncogenic phenotype. However, it is unclear at what stage in disease overexpression of the EGFR is most critical. To assess its role as an initiator of reproductive tissue tumor development, transgenic mice were derived with mouse mammary tumor virus (MMTV)‐regulated overexpression of the human EGFR. Although elevated expression of the EGFR in hormonally responsive tissues was observed, only one EGFR transgenic mouse developed a visible tumor over a 2‐year period. However, of 12 females monitored over the same time, hyperplasia, hypertrophy, or slight dysplasia was found in mammary glands of 55% of the animals examined, in the uterus or uterine horn of 89%, and in ovaries or oviducts of 100%. None of the reproductive tissues of the male transgenic animals or age‐matched, normal mice displayed these changes. These results revealed a role for the EGFR in the initiation of ovarian and uterine cancer and supported previous studies in breast cancer that the receptor can contribute to the neoplastic process in a significant albeit incremental way. J. Cell. Biochem. 103: 2010–2018, 2008. © 2007 Wiley‐Liss, Inc.

[1]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[2]  P. Mróz,et al.  Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice. , 2006, Cancer research.

[3]  E. Small,et al.  Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone‐refractory prostate cancer , 2006, Cancer.

[4]  Á. Ruibal,et al.  La expresión del receptor del factor de crecimiento epidérmico (EGFR) en carcinomas mamarios hormonoindependientes , 2006 .

[5]  L. Hudson,et al.  Epithelial cell migration in response to epidermal growth factor. , 2006, Methods in molecular biology.

[6]  M. Hung,et al.  EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization , 2006, Breast Cancer Research and Treatment.

[7]  S. Hammes,et al.  Epidermal growth factor receptor signaling is required for normal ovarian steroidogenesis and oocyte maturation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Knecht,et al.  Cancer of the uterine cervix is susceptible to anti-EGF-R antibody EMD 55,900 therapy. , 2005, Anticancer research.

[9]  R. Dickson,et al.  Differential alteration of stem and other cell populations in ducts and lobules of TGFalpha and c-Myc transgenic mouse mammary epithelium. , 2005, Tissue & cell.

[10]  R. Keri,et al.  Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice , 2005, Oncogene.

[11]  S. Poulsen,et al.  Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. , 2005, Molecular human reproduction.

[12]  Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium , 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[13]  S. Parsons,et al.  c-Src and cooperating partners in human cancer. , 2004, Cancer cell.

[14]  Corinne Silva,et al.  Phosphorylation of Y845 on the Epidermal Growth Factor Receptor Mediates Binding to the Mitochondrial Protein Cytochrome c Oxidase Subunit II , 2004, Molecular and Cellular Biology.

[15]  W. Muller.  Expression of activated oncogenes in the murine mammary gland: transgenic models for human breast cancer , 1991, Cancer and Metastasis Reviews.

[16]  J. Baselga,et al.  The epidermal growth factor receptor as a target for therapy in breast carcinoma , 2004, Breast Cancer Research and Treatment.

[17]  R. Dickson,et al.  EGF receptor expression, regulation, and function in breast cancer , 2004, Breast Cancer Research and Treatment.

[18]  T. Mattfeldt,et al.  Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast , 2004, Virchows Archiv A.

[19]  M. Capecchi,et al.  Hoxa11 regulates stromal cell death and proliferation during neonatal uterine development. , 2004, Molecular endocrinology.

[20]  S. Pearson-White.  Snol, a novel alternatively spliced isoform of the ski proto-oncogene homolog, sno , 2003 .

[21]  Stefania Staibano,et al.  Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[23]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[24]  F. Leenders,et al.  Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation , 2000, Oncogene.

[25]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[26]  M. Matzuk,et al.  Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. , 1999, Development.

[27]  M. Maa,et al.  c-Src-mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function* , 1999, The Journal of Biological Chemistry.

[28]  Z. Werb,et al.  Signaling through the stromal epidermal growth factor receptor is necessary for mammary ductal development. , 1999, Development.

[29]  S. Parsons,et al.  c-Src, receptor tyrosine kinases, and human cancer. , 1999, Advances in cancer research.

[30]  L. Wiley,et al.  The EGFR gene family in embryonic cell activities. , 1997, Current topics in developmental biology.

[31]  M. Beato.  Chromatin structure and the regulation of gene expression: remodeling at the MMTV promoter , 1996, Journal of Molecular Medicine.

[32]  R. Cardiff,et al.  Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice , 1996, Molecular and cellular biology.

[33]  P. Leder,et al.  NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. , 1996, Oncogene.

[34]  N. Normanno,et al.  Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.

[35]  W. Muller,et al.  Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. , 1994, Molecular and cellular biology.

[36]  S. Pearson-White,et al.  SnoI, a novel alternatively spliced isoform of the ski protooncogene homolog, sno. , 1993, Nucleic acids research.

[37]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[38]  P. Schneider,et al.  Transgenic models of human cancer. , 1991, Princess Takamatsu symposia.

[39]  G. Merlino,et al.  TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas , 1990, Cell.

[40]  D. Lowy,et al.  Functional heterogeneity of proto-oncogene tyrosine kinases: the C terminus of the human epidermal growth factor receptor facilitates cell proliferation. , 1989, Molecular and cellular biology.

[41]  J. Farndon,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.